Assembly Biosciences director granted 8,000 stock options

ASSEMBLY BIOSCIENCES, INC. director Susan Mahony received a grant of stock options covering 8,000 shares of common stock.

Accepted by SEC EDGAR 06/05/2026 - 04:50 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

ASSEMBLY BIOSCIENCES, INC. director Susan Mahony received a grant of stock options covering 8,000 shares of common stock. The options have an exercise price of $24.11 per share and expire on June 4, 2036.

The options vest, assuming continuous service, upon the earlier of June 4, 2027 or the date of the company’s 2027 annual meeting of stockholders. Following this grant, Mahony holds 8,000 stock options directly.

Insider Trade Summary

Grant/Award: 8,000 shares

Grant/Award 1 txn

Insider Mahony Susan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	8,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 8,000 contracts (Direct)

Footnotes (1)

F1. Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders.

Key Figures

Stock options granted: 8,000 options Underlying shares: 8,000 shares Exercise price: $24.11 per share +3 more

6 metrics

Stock options granted 8,000 options Grant to director Susan Mahony

Underlying shares 8,000 shares Common Stock underlying the options

Exercise price $24.11 per share Stock option exercise price

Expiration date June 4, 2036 Option term end date

Post-grant option holdings 8,000 options Total options following transaction

Vesting date trigger June 4, 2027 Earlier of this date or 2027 annual meeting

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, annual meeting of stockholders, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 24.1100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual meeting of stockholders financial

"the Issuer's 2027 annual meeting of stockholders."

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ASSEMBLY BIOSCIENCES (ASMB) report for Susan Mahony?

ASSEMBLY BIOSCIENCES reported that director Susan Mahony received a grant of stock options for 8,000 shares. These options are a form of equity compensation and give her the right to buy common stock at a fixed exercise price in the future.

How many ASMB shares are covered by Susan Mahony’s new stock options?

Susan Mahony’s new stock option grant covers 8,000 shares of ASSEMBLY BIOSCIENCES common stock. This means she can purchase up to 8,000 shares at the specified exercise price if the options vest and she chooses to exercise them.

What is the exercise price and expiration date of Susan Mahony’s ASMB options?

The granted stock options have an exercise price of $24.11 per share and expire on June 4, 2036. This fixed price allows Mahony to buy shares at $24.11 any time after vesting and before the expiration date, subject to plan terms.

When do Susan Mahony’s ASSEMBLY BIOSCIENCES stock options vest?

The stock options vest, assuming continuous service, on the earlier of June 4, 2027 or the date of ASSEMBLY BIOSCIENCES’ 2027 annual meeting of stockholders. Vesting must occur before she can exercise the options to acquire common shares.

Is Susan Mahony’s ASMB option grant an open-market stock purchase or sale?

No, this filing shows a grant of stock options as compensation, not an open-market purchase or sale of existing shares. The options give her the right to buy shares in the future; no public-market trade occurred in this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mahony Susan

(Last)

(First)

(Middle)

C/O ASSEMBLY BIOSCIENCES, INC.

TWO TOWER PLACE, 7TH FLOOR

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ASSEMBLY BIOSCIENCES, INC. [ ASMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$24.11	06/04/2026		A		8,000		⁽¹⁾	06/04/2036	Common Stock	8,000	$0	8,000	D

Explanation of Responses:

1. Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders.

	/s/ John O. Gunderson, as Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR